Sven Bilke1, Qing-Rong Chen, Jun S Wei, Javed Khan. 1. Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland, USA.
Abstract
PURPOSE: Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease. The goal of this study is to develop a DNA copy number-based prognostic profile for these patients. EXPERIMENTAL DESIGN: We have used comparative genomic hybridization to identify genome copy number changes that can predict outcome in patients with stage IV neuroblastoma without MYCN amplification. RESULTS: A strong correlation of patient survival with the presence of whole chromosome changes (WCC >or=2) was observed, even in the group of patients older than 500 days at time of diagnosis. This novel prognostic marker showed a significant dependence on the date of diagnosis; patients with WCC >or=2 diagnosed after 1998 had a significantly higher probability of survival compared with those diagnosed earlier. At the same time, no such time dependence was found among the samples with WCC <2, suggesting that medical progress patients in recent years has particularly benefited those patients with a stage IV non-MYCN-amplified disease if WCC >or=2 were present. CONCLUSIONS: In this pilot study, we present a novel prognostic marker for survival of high-risk neuroblastoma patients over the age of 500 days without MYCN amplification and diagnosed after 1998. Further validation study is required to establish this risk stratification for these patients.
PURPOSE:Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease. The goal of this study is to develop a DNA copy number-based prognostic profile for these patients. EXPERIMENTAL DESIGN: We have used comparative genomic hybridization to identify genome copy number changes that can predict outcome in patients with stage IV neuroblastoma without MYCN amplification. RESULTS: A strong correlation of patient survival with the presence of whole chromosome changes (WCC >or=2) was observed, even in the group of patients older than 500 days at time of diagnosis. This novel prognostic marker showed a significant dependence on the date of diagnosis; patients with WCC >or=2 diagnosed after 1998 had a significantly higher probability of survival compared with those diagnosed earlier. At the same time, no such time dependence was found among the samples with WCC <2, suggesting that medical progress patients in recent years has particularly benefited those patients with a stage IV non-MYCN-amplified disease if WCC >or=2 were present. CONCLUSIONS: In this pilot study, we present a novel prognostic marker for survival of high-risk neuroblastomapatients over the age of 500 days without MYCN amplification and diagnosed after 1998. Further validation study is required to establish this risk stratification for these patients.
Authors: D Plantaz; J Vandesompele; N Van Roy; M Lastowska; N Bown; V Combaret; M C Favrot; O Delattre; J Michon; J Bénard; O Hartmann; J C Nicholson; F M Ross; C Brinkschmidt; G Laureys; H Caron; K K Matthay; B G Feuerstein; F Speleman Journal: Int J Cancer Date: 2001-03-01 Impact factor: 7.396
Authors: L C Bowman; R P Castleberry; A Cantor; V Joshi; S L Cohn; E I Smith; A Yu; G M Brodeur; F A Hayes; A T Look Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Jun S Wei; Braden T Greer; Frank Westermann; Seth M Steinberg; Chang-Gue Son; Qing-Rong Chen; Craig C Whiteford; Sven Bilke; Alexei L Krasnoselsky; Nicola Cenacchi; Daniel Catchpoole; Frank Berthold; Manfred Schwab; Javed Khan Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: Yael P Mosse; Sharon J Diskin; Nora Wasserman; Katherine Rinaldi; Edward F Attiyeh; Kristina Cole; Jayanti Jagannathan; Karishma Bhambhani; Cynthia Winter; John M Maris Journal: Genes Chromosomes Cancer Date: 2007-10 Impact factor: 5.006
Authors: N Tomioka; S Oba; M Ohira; A Misra; J Fridlyand; S Ishii; Y Nakamura; E Isogai; T Hirata; Y Yoshida; S Todo; Y Kaneko; D G Albertson; D Pinkel; B G Feuerstein; A Nakagawara Journal: Oncogene Date: 2007-07-16 Impact factor: 9.867
Authors: Qing-Rong Chen; Sven Bilke; Jun S Wei; Craig C Whiteford; Nicola Cenacchi; Alexei L Krasnoselsky; Braden T Greer; Chang-Gue Son; Frank Westermann; Frank Berthold; Manfred Schwab; Daniel Catchpoole; Javed Khan Journal: BMC Genomics Date: 2004-09-20 Impact factor: 3.969
Authors: Karin Schmelz; Joern Toedling; Matt Huska; Maja C Cwikla; Louisa-Marie Kruetzfeldt; Jutta Proba; Peter F Ambros; Inge M Ambros; Sengül Boral; Marco Lodrini; Celine Y Chen; Martin Burkert; Dennis Guergen; Annabell Szymansky; Kathy Astrahantseff; Annette Kuenkele; Kerstin Haase; Matthias Fischer; Hedwig E Deubzer; Falk Hertwig; Patrick Hundsdoerfer; Anton G Henssen; Roland F Schwarz; Johannes H Schulte; Angelika Eggert Journal: Nat Commun Date: 2021-11-23 Impact factor: 14.919
Authors: Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman Journal: Genome Med Date: 2009-07-27 Impact factor: 11.117
Authors: Paola Scaruffi; Sara Stigliani; Stefano Moretti; Simona Coco; Carla De Vecchi; Francesca Valdora; Alberto Garaventa; Stefano Bonassi; Gian Paolo Tonini Journal: BMC Cancer Date: 2009-12-15 Impact factor: 4.430